TrialOral oncology2015

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

Antonio Jimeno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.